Long-Term Tolvaptan Administration in Chinese patients with Autosomal Dominant Polycystic Kidney Disease :A Retrospective Study in Real Clinical Practice
This real-world analysis showed that tolvaptan appears to be effective in delaying the clinical course of ADPKD patients in China, extending the results of previous clinical trials in other populations.
Authors
- Yunming Xiao (ORCID: https://orcid.org/0000-0002-2887-301X)
- X. Shawn Liu (ORCID: https://orcid.org/0000-0002-2799-2519)
- Mengfei Li (ORCID: https://orcid.org/0000-0002-9073-4109)
- Mingyang Sun (ORCID: https://orcid.org/0000-0002-5638-677X)
- Qinggang Li
- Yiyu Huang
- Shaoyuan Cui
- Ming Guo
- Xiangmei Chen
- Hong Wang (13528)
- Shaopeng Zhou
Publication Details
- Journal
- Kidney & Blood Pressure Research
- Published
- 2026-03-03
- DOI
- https://doi.org/10.1159/000550806
- Primary Topic
- Genetic and Kidney Cyst Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China